Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dasatinib vs Imatinib in Newly Diagnosed CML (SPIRIT2)
NCT01460693Phase 3Completed
- Sponsor
- Newcastle University
- Start
- Aug 2008
- Primary completion
- Mar 2018
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of dasatinib in chronic myeloid leukemia (CML), sponsored by Newcastle University. Started Aug 2008; status: completed.
02
Drugs
dasatinib
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT01460693.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01460693.